Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure?

Vassart, Julie; Didembourg, Marie; Morimont, Laure; Brisbois, Clotilde; Jamart, Laurent; Lebreton, Aurélien; Mullier, François; Donis, Nathalie; Favresse, Julien; Dogné, Jean-Michel; Douxfils, Jonathan

doi:10.1016/j.thromres.2024.03.001

Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure?

Vassart, Julie

;

Didembourg, Marie

;

Morimont, Laure

;

Brisbois, Clotilde

;

Douxfils, Jonathan

;et.al.

(2024) Thrombosis research — Vol. 236, p. 236-239 (2024)

Files

VassartJThrombRes2024.pdf

Open Access
Adobe PDF
1.43 MB

Download

Details

Authors

Vassart, Julie
Author
Didembourg, Marie
Author
Morimont, Laure
Author
Brisbois, Clotilde
Author
Mullier, FrançoisUCLouvain
Author
Douxfils, Jonathan
Author

Abstract

(en) To the Editors, The phase 3 OCEANIC-AF trial (NCT05643573) of the investigational oral activated factor XI (FXIa) inhibitor asundexian (Bayer, Leverkusen, Germany) tested at the dose of 50 mg has been stopped early due to an inferior efficacy of asundexian versus the control arm (apixaban) for the prevention of strokes and systemic embolisms in patients with atrial fibrillation (AF). [...]

Affiliations

Citations

APA
Chicago
FWB

Vassart, J., Didembourg, M., Morimont, L., Brisbois, C., Jamart, L., Lebreton, A., Mullier, F., Donis, N., Favresse, J., Dogné, J.-M., & Douxfils, J. (2024). Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure? Thrombosis research, 236, 236-239. https://doi.org/10.1016/j.thromres.2024.03.001 (Original work published 2024)